Abstract
The treatment of many diseases owes much to the important medicines that have been derived from plants, cancer is no exception. Cancer is a class of diseases characterized by out-of-control cell growth. Researchers have developed many agents which have shown brilliant therapeutic results against cancerous cells out of which the microtubule-targeting agents (MTAs) have made significant contributions to cancer therapy over the past 50 years. These dynamic tubulin structures can be targeted for the treatment of cancer due to their critical role in mitosis and other cellular processes. MTAs cause stabilisation (MSAs) or depolymerisation (MDAs) of the microtubules and hence result in apoptosis. This therapy has been frequently used in the treatment of advanced ovarian, breast, lung, head and neck, and prostate cancer, and is increasingly being used in early stage disease. Taxanes (e.g. paclitaxel, docetaxel) and epothilones (e.g. ixabepilone) are microtubule-targeting agents, which disrupt cellular processes and induce apoptosis. Nocodazole, Chamaecypanone C, Discodermolide, Noscapine, Laulimalide, and Eribulin are similar natural agents with convincing therapeutic efficacy in this field. Collectively these findings suggest mechanisms and therapies by which growth conditions may contribute to resistance to rapid killing by microtubule-disrupting drugs.
Keywords: Apoptosis, cancer, depolymerisation, microtubule targeting agents, stabilization.
Current Drug Therapy
Title:Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Volume: 8 Issue: 3
Author(s): Verma Nitika and Khatri Kapil
Affiliation:
Keywords: Apoptosis, cancer, depolymerisation, microtubule targeting agents, stabilization.
Abstract: The treatment of many diseases owes much to the important medicines that have been derived from plants, cancer is no exception. Cancer is a class of diseases characterized by out-of-control cell growth. Researchers have developed many agents which have shown brilliant therapeutic results against cancerous cells out of which the microtubule-targeting agents (MTAs) have made significant contributions to cancer therapy over the past 50 years. These dynamic tubulin structures can be targeted for the treatment of cancer due to their critical role in mitosis and other cellular processes. MTAs cause stabilisation (MSAs) or depolymerisation (MDAs) of the microtubules and hence result in apoptosis. This therapy has been frequently used in the treatment of advanced ovarian, breast, lung, head and neck, and prostate cancer, and is increasingly being used in early stage disease. Taxanes (e.g. paclitaxel, docetaxel) and epothilones (e.g. ixabepilone) are microtubule-targeting agents, which disrupt cellular processes and induce apoptosis. Nocodazole, Chamaecypanone C, Discodermolide, Noscapine, Laulimalide, and Eribulin are similar natural agents with convincing therapeutic efficacy in this field. Collectively these findings suggest mechanisms and therapies by which growth conditions may contribute to resistance to rapid killing by microtubule-disrupting drugs.
Export Options
About this article
Cite this article as:
Nitika Verma and Kapil Khatri, Microtubule Targeting Agents: A Benchmark in Cancer Therapy, Current Drug Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/15748855113086660011
DOI https://dx.doi.org/10.2174/15748855113086660011 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Landscape of Natural Products against Coronaviruses: Perspectives in COVID-19 Treatment and Anti-viral Mechanism
Current Pharmaceutical Design Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials The Antitumor Effects of Icaritin Against Breast Cancer is Related to Estrogen Receptors
Current Molecular Medicine Tocilizumab Labeling with 99mTechnetium via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma
Anti-Cancer Agents in Medicinal Chemistry Biodistribution and Pharmacokinetics of PEG-10kDa-Cholecystokinin-10 in Rats After Different Routes of Administration
Current Drug Delivery S100A9 as a Pharmacological Target Molecule in Inflammation and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Lycopene: A Review of Its Potential as an Anticancer Agent
Current Medicinal Chemistry - Anti-Cancer Agents Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials Renal & Ocular Targets for Therapy in Wegeners Granulomatosis
Inflammation & Allergy - Drug Targets (Discontinued) Chemistry of Tumour Targeted T1 Based MRI Contrast Agents
Current Topics in Medicinal Chemistry Interleukin 2 in Cancer Therapy
Current Medicinal Chemistry Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors
Current Cancer Drug Targets The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens
Current Pharmaceutical Design Alteration of Ceramide 1-O-Functionalization as a Promising Approach for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry The Thyroid Gland: A Crossroad in Inflammation-Induced Carcinoma? An Ongoing Debate with New Therapeutic Potential.
Current Medicinal Chemistry Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
Reviews on Recent Clinical Trials Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenomics of Xenobiotic Metabolizing Enzymes in South American Populations
Current Pharmacogenomics